Nanobiotix Receives Approval From ANSM to Start New Clinical Trial With Lead Product NBTXR3
PARIS--(Marketwired - Jun 13, 2013) - NANOBIOTIX (EURONEXT PARIS: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that...(more)
NANOBIOTIX
Jun 13, 2013 02:00 ET